Lotta Vrang

3.0k total citations
78 papers, 2.3k citations indexed

About

Lotta Vrang is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Lotta Vrang has authored 78 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Infectious Diseases, 40 papers in Virology and 24 papers in Molecular Biology. Recurrent topics in Lotta Vrang's work include HIV/AIDS drug development and treatment (53 papers), HIV Research and Treatment (40 papers) and HIV/AIDS Research and Interventions (11 papers). Lotta Vrang is often cited by papers focused on HIV/AIDS drug development and treatment (53 papers), HIV Research and Treatment (40 papers) and HIV/AIDS Research and Interventions (11 papers). Lotta Vrang collaborates with scholars based in Sweden, Belgium and United States. Lotta Vrang's co-authors include Bertil Samuelsson, B. Öberg, Bo Öberg, Anders Hallberg, Elizabeth Hamelink, U. Helena Danielson, Åsa Rosenquist, Torsten Unge, Jyoti Chattopadhyaya and Hong Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Analytical Biochemistry.

In The Last Decade

Lotta Vrang

76 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lotta Vrang Sweden 26 1.2k 795 709 667 540 78 2.3k
Akbar Ali United States 28 1.1k 0.9× 684 0.9× 1.2k 1.7× 367 0.6× 481 0.9× 53 2.6k
Joseph A. Martin United Kingdom 21 1.0k 0.8× 635 0.8× 784 1.1× 582 0.9× 388 0.7× 42 2.1k
Warren M. Kati United States 32 1.4k 1.1× 791 1.0× 1.6k 2.3× 661 1.0× 993 1.8× 81 3.5k
William E. Kohlbrenner United States 19 924 0.7× 695 0.9× 774 1.1× 521 0.8× 353 0.7× 34 1.9k
Manos Perros United Kingdom 21 1.3k 1.1× 1.6k 2.0× 688 1.0× 228 0.3× 383 0.7× 35 2.5k
E.A. Nalivaika United States 24 1.4k 1.1× 1.3k 1.6× 911 1.3× 199 0.3× 276 0.5× 39 2.1k
Paul L. Darke United States 34 1.3k 1.0× 1.1k 1.3× 1.4k 2.0× 756 1.1× 369 0.7× 63 2.8k
Deborah A. Paul United States 17 1.5k 1.2× 1.6k 2.0× 433 0.6× 280 0.4× 516 1.0× 22 2.3k
B. Govinda Rao United States 18 716 0.6× 339 0.4× 564 0.8× 252 0.4× 510 0.9× 38 1.7k
Jay A. Grobler United States 30 2.6k 2.1× 1.9k 2.4× 1.4k 1.9× 350 0.5× 750 1.4× 61 3.7k

Countries citing papers authored by Lotta Vrang

Since Specialization
Citations

This map shows the geographic impact of Lotta Vrang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lotta Vrang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lotta Vrang more than expected).

Fields of papers citing papers by Lotta Vrang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lotta Vrang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lotta Vrang. The network helps show where Lotta Vrang may publish in the future.

Co-authorship network of co-authors of Lotta Vrang

This figure shows the co-authorship network connecting the top 25 collaborators of Lotta Vrang. A scholar is included among the top collaborators of Lotta Vrang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lotta Vrang. Lotta Vrang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kylefjord, Helen, Genadiy Kalayanov, Lotta Vrang, et al.. (2015). P0688 : Preclinical characterisation of MIV-802, a novel uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection. Journal of Hepatology. 62. S580–S580. 1 indexed citations
2.
Kylefjord, Helen, et al.. (2013). Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a. Journal of Virological Methods. 195. 156–163. 3 indexed citations
3.
Abdurakhmanov, Eldar, et al.. (2013). Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Research. 97(3). 356–368. 14 indexed citations
4.
Sund, Christian, Oscar Belda, Neera Borkakoti, et al.. (2012). Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side 4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates. Bioorganic & Medicinal Chemistry Letters. 22(21). 6721–6727. 8 indexed citations
5.
Gossas, Thomas, Lotta Vrang, Ian Henderson, et al.. (2011). Aliskiren displays long-lasting interactions with human renin. Naunyn-Schmiedeberg s Archives of Pharmacology. 385(2). 219–224. 5 indexed citations
6.
Vrang, Lotta, et al.. (2010). Quantification of interactions between drug leads and serum proteins by use of “binding efficiency”. Analytical Biochemistry. 409(2). 163–175. 12 indexed citations
7.
Adolfsson, Hans, Katarina Jansson, Jimmy Lindberg, et al.. (2010). Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) Scaffold: Exploration of P1′ alkoxy residues and an aminoethylene (AE) central core. Bioorganic & Medicinal Chemistry. 18(4). 1711–1723. 11 indexed citations
8.
Wallberg, Hans, Lotta Vrang, Stefan Oscarson, et al.. (2009). Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors. European Journal of Medicinal Chemistry. 45(1). 160–170. 13 indexed citations
9.
Johansson, Per-Ola, Marcus Bäck, Ingemar Kvarnström, et al.. (2006). Potent inhibitors of the hepatitis C virus NS3 protease: Use of a novel P2 cyclopentane-derived template. Bioorganic & Medicinal Chemistry. 14(15). 5136–5151. 13 indexed citations
10.
Wannberg, Johan, Yogesh Sabnis, Lotta Vrang, et al.. (2006). A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-Substituted P1/P1′ side chains. Bioorganic & Medicinal Chemistry. 14(15). 5303–5315. 23 indexed citations
11.
Muthas, Daniel, Yogesh Sabnis, Elizabeth Hamelink, et al.. (2005). Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II. Bioorganic & Medicinal Chemistry. 13(18). 5371–5390. 30 indexed citations
12.
Oscarson, Stefan, et al.. (2003). New potent C2-Symmetric malaria plasmepsin I and II inhibitors. Bioorganic & Medicinal Chemistry. 11(7). 1235–1246. 25 indexed citations
13.
Kvarnström, Ingemar, Lotta Vrang, Elizabeth Hamelink, et al.. (2003). Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II. Bioorganic & Medicinal Chemistry. 11(6). 827–841. 14 indexed citations
14.
Kim, Eun‐Young, Lotta Vrang, Bo Öberg, & Thomas C. Merigan. (2001). Anti-HIV Type 1 Activity of 3′-Fluoro-3′-Deoxythymidine for Several Different Multidrug-Resistant Mutants. AIDS Research and Human Retroviruses. 17(5). 401–407. 24 indexed citations
15.
Hämäläinen, Markku, Per-Olof Markgren, Wesley Schaal, et al.. (2000). Characterization of a Set of HIV-1 Protease Inhibitors Using Binding Kinetics Data from a Biosensor-Based Screen. SLAS DISCOVERY. 5(5). 353–359. 37 indexed citations
16.
Zhang, Hong, Lotta Vrang, Kristina Bäckbro, et al.. (1995). Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Research. 28(4). 331–342. 37 indexed citations
17.
18.
Bäckbro, Kristina, Torsten Unge, Ramagauri Bhikhabhai, et al.. (1993). Disruption of a Salt Bridge between Asp 488 and Lys 465 in HIV-1 Reverse Transcriptase Alters Its Proteolytic Processing and Polymerase Activity. Virology. 196(2). 731–738. 4 indexed citations
19.
Harmenberg, Johan, et al.. (1990). Synergistic Inhibition of Human Immunodeficiency Virus Replication In Vitro by Combinations of 3′-Azido-3′-Deoxythymidine and 3′-Fluoro-3′-Deoxythymidine. AIDS Research and Human Retroviruses. 6(10). 1197–1202. 24 indexed citations
20.
Öberg, B. & Lotta Vrang. (1990). Screening for new agents. European Journal of Clinical Microbiology & Infectious Diseases. 9(7). 466–471. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akbar Ali Breakdown of academic impact, for papers by Joseph A. Martin Breakdown of academic impact, for papers by Warren M. Kati Breakdown of academic impact, for papers by William E. Kohlbrenner Breakdown of academic impact, for papers by Manos Perros Breakdown of academic impact, for papers by E.A. Nalivaika Breakdown of academic impact, for papers by Paul L. Darke Breakdown of academic impact, for papers by Deborah A. Paul Breakdown of academic impact, for papers by B. Govinda Rao Breakdown of academic impact, for papers by Jay A. Grobler
Rankless by CCL
2026